Lipid predictors of coronary heart disease and tibolone users

European Heart Journal, Supplement

Volumn 3, Issue M, 2001, Pages

  Crook, David ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Coronary heart disease; High density lipoprotein; Hormone replacement therapy; Lipids; Tibolone

Indexed keywords

HIGH DENSITY LIPOPROTEIN; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PLACEBO; TIBOLONE;

ACCURACY; CARDIOVASCULAR FUNCTION; CHOLESTEROL BLOOD LEVEL; CONFERENCE PAPER; ESTROGEN THERAPY; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; LIPOPROTEIN METABOLISM; PREDICTION; PRIORITY JOURNAL;

EID: 0035156938     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1520-765X(01)90079-3     Document Type: Conference Paper

References (23)

1. The protective effects of estrogen on the cardiovascular system
2. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women
3. Postmenopausal hormone replacement therapy and coronary heart disease: Clinical implications of recent randomized trial results
4. Tibolone prevents atherosclerotic lesion formation in cholesterol-fed, ovariectomized rabbits
5. A comparison of tibolone and conjugated equine estrogens on coronary artery atherosclerosis and bone density of postmenopausal monkeys
6. Livial: A review of clinical studies
7. Cardiovascular risk assessment for postmenopausal hormone replacement therapies such as tibolone (Livial)
8. A comparison of the effects of two continuous HRT regimens on cardiovascular risk factors
9. Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause
10. A double-blind crossover study on the effects of ORG OD14 compared to oestradiol valerate and placebo on lipid and carbohydrate metabolism in oophorectomized women
11. High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport
12. Molecular physiology of reverse cholesterol transport
13. Overexpression of apolipoprotein All in transgenic mice converts high density lipoproteins to proinflammatory particles
14. ApoA-I knockout mice: Characterization of HDL metabolism in homozygotes and identification of a post-RNA mechanism of apoA-I up-regulation in heterozygotes
15. Decreased atherosclerosis in heterozygous low density lipoprotein receptor-deficient mice expressing the scavenger receptor B1 transgene
16. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
17. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: The Diabetes Atherosclerosis Intervention Study, a randomised study
18. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: The Bezafibrate Infarction Prevention (BIP) study
19. Diabetes, hyperinsulinemia and recurrent coronary events in the VA-High Density Lipoprotein Trial (VA-HIT)
20. The effect of probucol on femoral atherosclerosis: The Probucol Quantitative Regression Swedish Trial (PQRST)
21. Differential effect of National Cholesterol Education Program (NCEP) step II diet on HDL cholesterol, its subfractions, and apoprotein A-I levels in hypercholesterolemic women and men after 1 year: The beFIT Study
22. Tibolone lowers HDL concentrations but does not impair cholesterol efflux from cells
23. Probucol promotes reverse cholesterol transport in heterozygous familial hyper-cholesterolemia. Effects on apolipoprotein AI-containing lipoprotein particles